Derbyshire-based N4 Pharma has launched a broker offer to raise a maximum of £1 million.
It is initially expected that £0.25 million will be raised in the offer, though if oversubscribed it may be extended.
The issue price of the broker offer is 2 pence per new ordinary share.
Turner Pope Investments (TPI) Limited is agent for the company.
N4 Pharma is a specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines.
We offer an exciting opportunity in the East Midlands for companies to plan innovative advertising campaigns alongside consistently excellent reporting. Our newsletters are sent directly chief executives, chairmen, managing directors and senior managers across the East Midlands. We also reflect on the importance of SMEs, with numerous companies from all sectors – from manufacturing to technology – benefiting from our mix of news and features. If you’re in business, East Midlands Business Link is for you.
Contact us: sales@blmgroup.co.uk
© Copyright 2025 - East Midlands Business Link
By continuing to use the site, you agree to the use of cookies. more information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
